Stem-Health Hellas, Hygeia Hospital, 4 Er. Stavrou & Kifisias Avenue, Athens, Greece.
Haematologica. 2011 Aug;96(8):1213-20. doi: 10.3324/haematol.2010.038836. Epub 2011 May 5.
Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. A disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low weight recipients, such as children. Various alternatives have been used to overcome this limitation, including co-infusion of two partially HLA-matched cord blood units. According to Eurocord Registry data, this strategy has been applied in approximately 993 adult patients with hematologic diseases since the first double umbilical cord blood transplantation in 1999. In fact, since 2005, the number of adult patients receiving double umbilical cord blood transplantation has surpassed the number of adults transplanted with single cord blood units. The engraftment rate is comparable for both single and double umbilical cord blood transplantation, although the latter is accompanied by a higher incidence of grade II acute graft-versus-host disease and lower leukemia relapse for patients in first complete remission. In the majority of patients undergoing double umbilical cord blood transplantation, transient chimerism, due to the presence of cells from both donor units early post transplant, is replaced by sustained dominance of one unit from which long-term hematopoiesis is derived. Although the biology and the factors that determine unit dominance have not been clarified, the implication of immune-mediated mechanisms has been reported. Preliminary data have demonstrated the safety of double umbilical cord blood transplantation. Ongoing clinical trials and prolonged follow up of the patients will clarify the immunology and determine the efficacy of this approach. We present here a brief overview of the clinical experience on double umbilical cord blood transplantation and its underlying biology.
脐带血移植在过去几年中越来越多地被用于治疗恶性和非恶性血液病及其他疾病,作为与不匹配相关或匹配无关的骨髓或外周血造血干细胞移植的替代方法。脐带血的一个缺点是其细胞含量低,这限制了脐带血移植只能用于一般体重较轻的受者,如儿童。为了克服这一限制,已经使用了各种替代方法,包括共输注两个部分 HLA 匹配的脐带血单位。根据 Eurocord 注册中心的数据,自 1999 年首例双脐带血移植以来,该策略已应用于约 993 例血液病成年患者。事实上,自 2005 年以来,接受双脐带血移植的成年患者数量已经超过了接受单个脐带血单位移植的成年患者数量。单脐血和双脐血移植的植入率相当,尽管后者伴有更高的 II 级急性移植物抗宿主病发生率和首次完全缓解的患者更低的白血病复发率。在大多数接受双脐带血移植的患者中,由于移植后早期两个供者单位的细胞存在,短暂的嵌合体被一个单位的持续优势所取代,长期造血来源于该单位。尽管尚未阐明决定单位优势的生物学和因素,但已经报道了免疫介导机制的影响。初步数据表明双脐带血移植是安全的。正在进行的临床试验和对患者的长期随访将阐明这种方法的免疫学和确定其疗效。我们在这里简要概述了双脐带血移植及其基础生物学的临床经验。